Résumés
Résumé
Les benzodiazépines sont souvent prescrites pour le traitement à court terme du Trouble d’anxiété généralisée (TAG). La nature chronique du TAG entraîne une prise prolongée de ces psychotropes sur plusieurs mois et plusieurs années, entraînant ainsi une dépendance psychologique et physique. La présente étude vise à déterminer si la combinaison d’une thérapie comportementale et cognitive et d’un sevrage médicamenteux graduel facilite l’arrêt des benzodiazépines chez les patients souffrant d’un TAG. Au total, cinq participants ont reçu l’intervention combinée selon un protocole expérimental à cas uniques avec niveaux de base multiples. Quatre d’entre eux ont complété le plan de sevrage et ont démontré des améliorations cliniques importantes. Les données recueillies lors des suivis 3 et 6 mois indiquent un maintien des gains thérapeutiques. Ces résultats suggèrent que la thérapie comportementale et cognitive facilite l’arrêt des benzodiazépines chez les patients présentant un TAG tout en diminuant significativement les symptômes anxieux.
Abstract
Benzodiazepine medication is often prescribed for the short-term treatment of generalized anxiety disorder. The chronic nature of generalized anxiety disorder entails a prolonged use of these psychotropic medication on several months and several years, entailing also a psychological and physical addiction. The current study aims at determining if the combination of a behavioral and cognitive therapy and gradual withdrawal facilitate interrupting the use of benzodiazepine in patients with generalized anxiety disorder. In total, five participants have received the combined intervention according to an experimental protocol of unique case with multiple levels. Four among them have completed the withdrawal plan and have demonstrated important clinical improvements. Data collected during the 3rd and 6th month indicate the preservation of therapeutic gain. These results suggest that behavioral and cognitive therapy facilitates stopping the use of benzodiazepine medication in patients with generalized anxiety disorder by significantly reducing anxious symptoms.
Resumen
Las benzodiacepinas son con frecuencia prescritas para el tratamiento a corto plazo del Trastorno de ansiedad generalizada (TAG). La naturaleza crónica del TAG provoca la toma prolangada de estos psicotrópicos durante varios meses y varios años, ocasionando de esta manera una dependencia psicológica y física. El presente estudio busca determinar si la combinación de una terapia comportamental y cognitiva y una abstinencia gradual de medicamentos facilita la suspensión de las benzodiazepinas en los pacientes que sufren de un TAG. En total, cinco participantes recibieron la intervención combinada según un protocolo experimental de casos únicos con líneas de base múltiples. Cuatro de ellos completaron el plan de reducción y demostraron mejoras clínicas importantes. Los datos recopilados durante el seguimiento de 3 y 6 meses indican un mantenimiento de los beneficios terapéuticos. Estos resultados sugieren que la terapia comportamental y cognitiva facilita la suspensión de las benzodiacepinas en los pacientes que presentan un TAG al mismo tiempo que disminuyen significativamente los síntomas de ansiedad.
Resumo
As benzodiazepinas são freqüentemente prescritas para o tratamento a curto prazo do Transtorno de ansiedade generalizada (TAG). A natureza crônica do TAG leva a uma utilização prolongada dos psicotrópicos durante vários meses e anos, levando assim a uma dependência psicológica e física. O presente estudo visa determinar se a combinação de uma terapia comportamental e cognitiva e uma desabituação médica gradual facilita a interrupção no uso das benzodiazepinas nos pacientes que sofrem de um TAG. No total, cinco participantes receberam a intervenção combinada segundo um protocolo experimental em casos únicos com níveis de base múltiplas. Quatro dentre eles completaram o plano de desabituação e demonstraram melhorias clínicas importantes. Os dados recolhidos após três e seis meses, indicam uma manutenção dos ganhos terapêuticos. Estes resultados sugerem que a terapia cognitivo-comportamental facilita a interrupção no uso de benzodiazepinas em pacientes que apresentam um TAG e ao mesmo tempo diminuem em muito os sintomas de ansiedade.
Parties annexes
Références
- American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders (4e édition), Washinton, DC.
- Ashton, C. H., 1991, Protrated withdrawal syndromes from benzodiazepine, Journal of Substance Abuse Treatment, 8, 9-17.
- Ashton, C. H., 2001, Benzodiazepines : How they Work and How to Withdraw, Newcastle Upon Tyne, Newcastle University.
- Baillargeon, L., Landreville, P., Verreault, R., Beauchemin, J.-P., Grégoire, J.-P., Morin, C. M., 1998, Réduction de la consommation de benzodiazépines chez les aîné(e)s souffrant d’insomnie : effets d’une intervention cognitive et comportementale combinée avec un sevrage médicamenteux, Recherche financée par Santé Canada dans le cadre du Programme National de Recherche et de Développement en Matière de Santé (PNRDS).
- Beck, A. T., Epstein, N., Brown, G., Steer, R. A., 1988, An inventory for measuring clinical anxiety : Psychometric properties, Journal of Consulting and Clinical Psychology, 56, 893-897.
- Beck, A. T., Rush, A. J., Shaw, B. F., Emery, G., 1979, Cognitive Therapy of Depression, New York, Guilford Press.
- Beck, A. T., Steer, R. A., Brown, G. K., 1996, Beck Depression Inventory Manual, 2e éd., San Antonio, Texas, Psychological Corporation.
- Bradwejn, J., Berner, M., Shaw, B., 1992, Malade d’inquiétude : Guide du médecin pour le traitement et le counseling, Grosvenor Inc., Montréal.
- Brown, T. A., Barlow, D. H., 1992, Comorbidity among anxiety disorders : implications for treatment and DSM-IV, Journal of Consulting and Clinical Psychology, 60, 835-844.
- Brown, T. A., Di Nardo, P. A., Barlow, D. H., 1994, Anxiety Disorders Interview Schedule for DSM-IV, Albany, Graywind Publications.
- Bruce, T. J., Spiegel, D. A., Hegel, M. T., 1999, Cognitive behavior therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation : a long-term follow-up of the Peoria and Datmouth studies, Journal of Consulting and Clinical Psychology, 67, 151-156.
- Busto, U., Sellers, E. M., 1991, Pharmacologic aspects of benzodiazepine tolerance and dependence, Journal of Substance Abuse Treatment, 8, 29-33.
- Casacalenda, N., Boulenger, J.-P., 1998, Pharmacologic treatments effective in both Generalized Anxiety Disorder and Major Depressive Disorder : Clinical and theoretical implications, Canadian Journal of Psychiatry, 43, 722-730.
- Christensen, L., Mendoza, J. L., 1986, A method of assessing change in a single subject : An alteration of the RC index, Behavior Therapy, 17, 305-308.
- Craske, M. G., Barlow, D. H., O’Leary, T., 1992, Mastery of your Anxiety and Worry, Albany, Graywind Publications.
- Dozois, D. J. A., Dobson, K. S., Ahnberg, J. L., 1998, A Psychometric evaluation of the Beck Depression Inventory-II, Psychological Assessment, 10, 83-89.
- Dugas, M. J., Freeston, M. H., Ladouceur, R., 1997, Intolerance of uncertainty and problem orientation in worry, Cognitive Therapy and Research, 21, 593-606.
- Dugas, M. J., Freeston, M. H., Provencher, M. D., Lachance, S., Ladouceur, R., Gosselin, P., 2001, Le questionnaire sur l’inquiétude et l’anxiété : validation dans des échantillons non cliniques et cliniques, Journal de thérapie comportementale et cognitive, 11, 31-36.
- Dugas, M. J., Ladouceur, R., 2000, Treatment of GAD : Targeting intolerance of uncertainty in two types of worry, Behavior Modification, 24, 635-657.
- Dugas, M. J., Letarte, H., Rhéaume, J., Freeston, M. H., Ladouceur, R., 1995, Worry and problem-solving : Evidence of a specific Relationship, Cognitive Therapy and Research, 19, 109-120.
- Feinstein, R., E., 1999, Cognitive and mental disorders due to general medical conditions, in Cutler, J. L., Marcus, E. R., eds., Psychiatry, Philadelphia, W.B.Saunders company, 102-103.
- Freeston, M. H., Ladouceur, R., Thibodeau, N., Gagnon, F., Rhéaume, J., 1994a, L’Inventaire d’Anxiété de Beck : Propriétés psychométriques d’une traduction française, L’Encéphale, 20, 47-55.
- Freeston, M.H., Rhéaume, J., Letarte, H., Dugas, M.J., Ladouceur, R., 1994b, Why do people worry ? Personality and Individual Differences, 17, 791-802.
- Gosselin, P., Dugas, M. J., Ladouceur, R., Freeston, M. H., 2001, Évaluation des inquiétudes : validation d’une traduction française du Penn State Worry Questionnaire, L’Encéphale, 27, 475-484.
- Gosselin, P., Laberge, B., 2003, Les facteurs étiologiques du Trouble d’anxiété généralisée : état actuel des connaissances, L’Encéphale, 29, 351-361.
- Gosselin, P., Ladouceur, R., 2001, Medication Use Among GAD Patients, Communication présentée au World Congress of Behavioral and Cognitive Therapies, Vancouver, BC.
- Gosselin, P., Ladouceur, R., Langlois, F., Freeston, M.H., Dugas, M. J., Bertrand, J., sous presse, Pourquoi s’inquiéter ? Développement et validation d’un nouvel instrument évaluant les croyances à l’égard des inquiétudes, European Review of Applied Psychology.
- Gosselin, P., Langlois, F., Freeston, M. H., Ladouceur, R, Dugas, M. J., Pelletier, O., 2002, Le Questionnaire d’Évitement Cognitif (QEC) : Développement et validation auprès d’un échantillon d’adultes et d’adolescents, Journal de thérapie comportementale et cognitive, 12, 24-37.
- Gosselin, P., Pelletier, O., Ladouceur, R., 2001a, The Negative Problem Orientation Questionnaire (NOPQ) : Development and Validation among a Non-clinical Sample, Communication présentée au World Congress of Behavioral and Cognitive Therapies, Vancouver, BC.
- Gosselin, P., Pelletier, O., Ladouceur, R., 2001b, Développement et validation d’un nouveau questionnaire évaluant l’attitude des gens à l’égard des problèmes, Communication présentée au Réseau de Santé Mentale du FRSQ (RSMQ), Québec.
- Jacobson, N. S., Follette, W. C., Revenstorf, D., 1984, Psychotherapy outcome research : Methods for reporting variability and evaluating clinical significance, Behavior Therapy, 15, 336-352.
- Jacobson, N. S., Truax, P., 1991, Clinical significance : a statistical approach to defining meaningful change in psychotherapy research, Journal of Consulting and Clinical Psychology, 59, 12-19.
- Kazdin, A. E., 1998, Research Design in Clinical Psychology, Boston, Allyn and Bacon.
- Ladouceur, R., Bégin, G., 1980, Protocoles de recherche en sciences appliquées et fondamentales, St-Hyacinthe, Edisem.
- Lydiard, R. B., Brawman-Mintzer, O., Ballenger, J. C., 1996, Recent developments in the psychopharmacology of anxiety disorders, Journal of Consulting and Clinical Psychology, 64, 660-668.
- Meyer, T. J., Miller, M. L., Metzger, R. L., Borkovec, T. D., 1990, Development and validation of the Penn State Worry Questionnaire, Behaviour Research and Therapy, 28, 487-495.
- Miller, N. S., 1995, Liability and efficacy from long-term use of benzodiazepines : Documentation and interpretation, Psychiatric Annals, 25, 166-173.
- Morin, C. M., Colecchi, C. A., Ling, W. D., Sood, R. K., 1995, Cognitive behavior therapy to facilitate benzodiazepine discontinuation among hypnotic-dependant patients with insomnia, Behavior Therapy, 26, 733-745.
- Otto, M. W., Pollack, M. H., Sachs, G. S. Reiter, S. R., Meltzer-Brody, S., Rosenbaum, J. F., 1993, Discontinuation of benzodiazepine treatment : efficacy of cognitive-behavioral therapy for patient with Panic Disorder, America Journal of Psychiatry, 150, 1485-1490.
- Rickels, K., DeMartinis, N., Rynn, M., Mandos, L., 1999, Pharmacologic strategies for discontinuing benzodiazepine treatment, Journal of Clinical Psychopharmacology, 19, 12S-16S.
- Russakoff, L. M., 1999, Psychopharmacology, in Cutler, J.L., Marcus, ER.R., eds., Psychiatry, Philadelphia, W.B.Saunders company, 327-330.
- Schweizer, E., 1995, Generalized Anxiety Disorder : Longitudinal course and pharmacologic treatment, in Pollack and Otto eds., The Psychiatric Clinics of North America, Anxiety Disorders : Longitudinal Course and Treatment, 18, 843-857.
- Spiegel, D. A., 1999, Psychological strategies for discontinuing benzodiazepine treatment, Journal of Clinical Psychopharmacology, 19, 17S-22S.
- Spiegel, D. A., Bruce, T. J., Gregg, S. F., Nuzzarello, A., 1994, Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in Panic Disorder ? American Journal of Psychiatry, 151, 876-881.
- Tallis, F., Eysenck, M. W., Mathews, A., 1992, A questionnaire for the measurement of nonpathological worry, Personality and Individual Differences, 13, 161-168.
- Westra, H. A., Stewart, S. H., 1998, Cognitive behavioural therapy and pharmacotherapy : Complimentary or contradictory approaches to the treatment of anxiety ?, Clinical Psychology Review, 18, 307-340.
- Whittal, M. L., Otto, M. W., Hong, J. J., 2001, Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder : a case series, Behaviour Research and Therapy, 39, 939-945.
- Wittchen, H.-U., Zhao, S., Kessler, R. C., Eaton, W. W., 1994, DSM-III-R Generalized anxiety disorder in the national comorbidity survey, Archives of General Psychiatry, 51, 355-364.